LENSAR, Inc. (LNSR)
- Business Wire
LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU
ORLANDO, Fla., September 08, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptive Cataract Treatment System ("ALLY" or the "ALLY System") in the European Union.
- Business Wire
First Patients Treated with LENSAR’s® ALLY™ Adaptive Cataract Treatment System
ORLANDO, Fla., August 16, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the first commercial cases performed with the ALLY™ Adaptive Cataract Treatment System ("ALLY" or the "ALLY System") by Robert Weinstock, MD at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted cataract surgery cases following the recent insta
- Business Wire
LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update
ORLANDO, Fla., August 08, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives.
